Showing 1-10 of 18 results for "".
DERM2020 Content Recap: Brad Glick, DO, MPH
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-brad-glick-do/19840/DERM2020 Faculty Brad Glick, DO, MPH shares his thoughts on DERM2020 and some of the presentations around COVID.- Brad Glick, DO, MPHhttps://practicaldermatology.com/profiles/brad-glick-do-mph/jJq5Gl/
Nail Disease and JAK Inhibitor Safety
https://practicaldermatology.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Comorbidities in Vitiligo
https://practicaldermatology.com/issues/august-2025/comorbidities-in-vitiligo/36702/Vitiligo is a chronic, acquired pigmentary disorder characterized by the progressive loss of function or destruction of melanocytes in the skin, hair follicles, and mucous membranes. In this piece, Dr. Brad Glick and colleagues explore comorbidities in vitiligo.Clinical Conversations: MOA of JAK Inhibitors in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-moa-of-jak-inhibitors-in-dermatology/20096/JAK inhibitors have a range of potential applications in clinical dermatology. In the first video of this series, Brad Glick, DO and Raj Chovatiya, MD explain the mechanism of action of JAK inhibitors and explain how they may be used topically or systemically to treat skin diseases like atopic dermaClinical Conversations: The Data for JAK Inhibitors in AD
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-the-data-for-jak-inhibitors-in-ad/20105/JAK inhibitors represent a new therapeutic class for the treatment of atopic dermatitis. Find out what the data show about their efficacy and tolerability in a conversation between Brad Glick, DO and Raj Chovatiya, MD. Discover how these drugs can fit into the treatment plan and how these experts di- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- Promising Pipeline for CSU Optionshttps://practicaldermatology.com/news/promising-pipeline-csu-options/2468488/Cleveland Clinic allergist Dr. David Lang joined Dr. Dawn Merritt and Dr. Brad P. Glick to discuss chronic spontaneous urticaria (CSU) at the 44th Annual Fall Clinical Dermatology Conference and noted that the future is very promising. “Our recent understanding of chronic urticaria has imp
- NPF Update: Group Hosts 25th Dermatology Residents’ Meeting and Research Symposium: A Cure for Allhttps://practicaldermatology.com/news/npf-update-group-hosts-25th-dermatology-residents-meeting-and-research-symposium-a-cure-for-all/2462049/The National Psoriasis Foundation (NPF) celebrated the 25th anniversary of the annual Dermatology Residents’ Meeting on October 7 and 8, 2023 in Washington, D.C. Experts and co-chairs Brad P. Glick, DO, MPH, FAAD, and Samuel Hwang MD, PhD. hosted the silver anniversary event with
DermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasis
- Prev
- Next